Stock Financial Ratios, Dividends, Split History

CIR / CIRCOR International, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price42.79
Volume446,400.00
Market Cap ($M)844.38
Enterprise Value ($M)1,552.92
Book Value ($M)592.10
Book Value / Share29.86
Price / Book1.40
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Common Stock Shares Outstanding 19,785,298
Weighted Average Number Diluted Shares Outstanding Adjustment 175,000
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Diluted Shares Outstanding 16,849,000
Common Shares Outstanding 19,793,160
Weighted Average Number Of Shares Outstanding Basic 16,674,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.01
Return on Assets (ROA)0.01
Return on Equity (ROE)0.03
Balance Sheet (mrq) ($M)
Assets1,928.11
Liabilities1,336.01
Quick Ratio1.24
Current Ratio2.04
Income Statement (mra) ($M)
Entity Wide Revenue Number Of Major Customer0.00
Revenues0.00
Sales Revenue Net661,710,000.00
Operating Income20.57
Net Income11.79
Earnings Per Share Basic0.71
Earnings Per Share Diluted0.70
Cash Flow Statement (mra) ($M)
Cash From Operations9.64
Cash from Investing-502.12
Cash from Financing-502.12
Identifiers and Descriptors
CUSIP17273K109
Central Index Key (CIK)1091883
Related CUSIPS
17273K909

Split History

Stock splits are used by CIRCOR International, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

CIRCOR International, Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-02 seekingalpha
The following slide deck was published by CIRCOR International, Inc. in conjunction with their 2018 Q1 earnings call. (5-0)

BRIEF-Circor International - Entered Interest Rate Swap Pursuant To International Swaps And Derivatives Association Master Agreement

2018-04-17 reuters
* CIRCOR INTERNATIONAL - EFFECTIVE APRIL 12, ENTERED INTEREST RATE SWAP PURSUANT TO INTERNATIONAL SWAPS AND DERIVATIVES ASSOCIATION MASTER AGREEMENT (5-0)

New Strong Sell Stocks for March 21st

2018-03-21 zacks
Ampco-Pittsburgh Corporation (AP - Free Report) is a manufacturer of custom designed engineering products to commercial and industrial users worldwide. The Zacks Consensus Estimate for its current year earnings has been revised 32.6% downward over the last 30 days. (57-0)

CUSIP: 17273K109